CalciMedica Inc. (NASDAQ:CALC) Stock Has Consensus Target Price of $50.00 According to Brokerages

Shares of CalciMedica Inc. (NASDAQ:CALC) have been given an average recommendation of “Hold” by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $50.00.

Several research analysts recently weighed in on CALC shares. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Guggenheim started coverage on CalciMedica in a research report on Thursday, August 20th. They set a “buy” rating on the stock. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. Finally, Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th.

CalciMedica Stock Performance

CALC stock opened at $1.30 on Tuesday. The company has a 50-day simple moving average of $1.64 and a 200 day simple moving average of $3.77. The company has a market capitalization of $8.88 million, a P/E ratio of -0.19 and a beta of 0.84. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. CalciMedica has a fifty-two week low of $1.00 and a fifty-two week high of $36.00.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.97. Sell-side analysts predict that CalciMedica will post -5.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. 180 Wealth Advisors LLC lifted its holdings in shares of CalciMedica Inc. (NASDAQ:CALC) by 297.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 126,500 shares of the company’s stock after purchasing an additional 94,650 shares during the quarter. 180 Wealth Advisors LLC owned approximately 0.80% of CalciMedica worth $68,000 as of its most recent SEC filing.

About CalciMedica

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.